Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | AOC2 | O75106 | 8/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 6/20 | 0.39 |
| ▸ | MMP13 | P45452 | 4/20 | 0.38 |
| ▸ | MMP1 | P03956 | 3/20 | 0.38 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.38 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466874 | 0.82 | GPR119 (0.55) | GPR119ADAM17MMP13MMP1 | |
| SCHEMBL6011648 | 0.80 | SLC6A4 (0.42) | ADAM17MMP13MMP1MMP2MMP9 | |
| Hydrochloric Acid SCHEMBL6011657 | 0.79 | SLC6A4 (0.41) | ADAM17MMP13MMP1MMP2MMP9 | |
| SCHEMBL6011397 | 0.78 | MEN1 (0.44) | GPR119AOC2MMP2 | |
| SCHEMBL7602931 | 0.72 | GPR119 (0.66) | GPR119MMP13 | |
| SCHEMBL6011714 | 0.72 | SMN1; SMN2 (0.51) | MMP1MMP2MMP9MMP8 | |
| SCHEMBL27143232 | 0.72 | ALDH1A1 (0.50) | GPR119 | |
| SCHEMBL6011498 | 0.71 | CCR5 (0.49) | — | |
| SCHEMBL3090147 | 0.71 | SIGMAR1 (0.62) | — | |
| SCHEMBL6011960 | 0.70 | KMT2A (0.60) | ADAM17MMP13MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189650-A1 | Novel piperidine derivatives as modulators of chemokine receptor ccr5 | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| EP-1572650-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056773-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189650-A1 | Novel piperidine derivatives as modulators of chemokine receptor ccr5 | CCR5, CCR2, CCR1 | GPR119 142/4885AOC2 4764/4885MAOA 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.